Loxo Oncology
AcquiredLoxo Oncology is a biotech company in United States, founded in 2013. It has raised $57.0M across 2 rounds, most recently a $24.0M Series B in May 2014.
- Employees
- 51–200
- Founded
- 2013
- Business Model
- B2B
- Website
- loxooncology.com
- Total Funding
- $57.0M
- Last Round
- $24.0M Series BMay 2014
- Rounds
- 2
- Acquisition Date
- Jan 2019
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 2 funding rounds and 4 investors for this company. The full record is or through the API.
About
Loxo Oncology was a biopharmaceutical company focused on developing precision oncology medicines targeting cancers driven by specific genetic abnormalities. Its pipeline included larotrectinib (VITRAKVI), the first FDA-approved tumor-agnostic TRK inhibitor. The company was acquired by Eli Lilly in February 2019 for approximately $8 billion.
Summary
It lists 51–200 employees. It has raised $57.0M in total across 2 rounds, most recently a $24.0M Series B round in May 2014. Investors include Aisling Capital, Eli Lilly and New Enterprise Associates.
Funding & Exit History
Jan 2019
Sign up to see all 4 events
Funding: Series A through Series B. Amounts, valuations, and investors where available.
Investors
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Novel bicyclic peptides and drug conjugates for cancer
China's leading blood products manufacturer
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/loxo-oncology"><img src="https://indexed.vc/api/badge/company/loxo-oncology" alt="Loxo Oncology on Indexed.vc" width="260" height="76" /></a>